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Background. Though recurrent Clostridium difficile infection (CDI) is common and poses a major clinical concern, data are 
lacking regarding mortality among patients who survive their initial CDI and have subsequent recurrences. Risk factors for mortality 
in patients with recurrent CDI are largely unknown.
Methods. Veterans Affairs patients with a first CDI (stool sample with positive C. difficile toxin(s) and ≥2 days CDI treatment) 
were included (2010–2014). Subsequent recurrences were defined as additional CDI episodes ≥14 days after the stool test date and 
within 30 days of the end of treatment. A matched (1:4) case–control analysis was conducted using multivariable conditional logistic 
regression to identify predictors of all-cause mortality within 30 days of the first recurrence.
Results. Crude 30-day all-cause mortality rates were 10.6% for the initial CDI episode, 8.3% for the first recurrence, 4.2% for the 
second recurrence, and 5.9% for the third recurrence. Among 110 cases and 440 controls, 6 predictors of mortality were identified: 
use of proton pump inhibitors (PPIs; odds ratio [OR], 3.86; 95% confidence interval [CI], 2.14–6.96), any antibiotic (OR, 3.33; 95% 
CI, 1.79–6.17), respiratory failure (OR, 8.26; 95% CI, 1.71–39.92), congitive dysfunction (OR, 2.41; 95% CI, 1.02–5.72), nutrition 
deficiency (OR, 2.91; 95% CI, 1.37–6.21), and age (OR, 1.04; 95% CI, 1.01–1.07).
Conclusions. In our national cohort of Veterans, crude mortality decreased by 44% from the initial episode to the third recur-
rence. Treatment with antibiotics, use of PPIs, and underlying comorbidities were important predictors of mortality in recurrent 
CDI. Our study assists health care providers in identifying patients at high risk of death after CDI recurrence.
Keywords. Clostridium difficile infection; mortality; predictors; recurrent disease; Veterans Affairs.
 
Clostridium difficile is a gram-positive, anaerobic, spore-form-
ing bacterium that causes infectious diarrhea ranging in 
severity from mild to life-threatening [1]. Disease recurrence 
and decreased survival are important concerns related to 
Clostridium difficile infection (CDI). It is estimated that C. dif-
ficile is responsible for at least half a million cases of infection 
in the United States annually [2]. The estimated number of 
first recurrences of CDI each year is 83 000, and the estimated 
number of deaths is 29 300 [2]. Symptomatic first recurrence 
after resolution of the primary CDI episode occurs in 20%–
30% of patients, usually within 30 days after treatment cessa-
tion [3–5]. Clostridium difficile infection mortality estimates 
vary widely in the literature, with rates ranging from less than 
5% to more than 20% in severe cases [6, 7]. A  review of 27 
studies found that the CDI-associated mortality rate was 6% 
within 3 months of diagnosis [8]. Previous work has identified 
several risk factors for mortality in patients with CDI [9–12]. 
Older age, non-CDI antibiotic use concomitantly or after CDI 
treatment, and presence of underlying comorbid conditions 
are among the most frequently reported mortality risk factors 
[9, 10].
Despite the common and growing concern of recurrent dis-
ease over the past decade, data are lacking regarding mortality 
rates among patients who survive their initial CDI episode and 
have subsequent recurrences [5]. The few previously reported 
mortality estimates among those with disease recurrence vary 
widely from approximately 5% to greater than 35%, likely due 
to the different patient populations studied and significant 
variations in follow-up for death from 30 days to 1 year pos-
trecurrence [13–16]. Moreover, although some studies sug-
gest that recurrence may increase risk of death, others suggest 
that recurrence may not increase risk of death and mortality 
rates may actually decrease as recurrences accrue [13, 15–18]. 
Finally, independent predictors of mortality among patients 
with CDI recurrence are largely unknown. Knowledge of these 
factors could improve the management of patients with recur-
rent disease and limit unfavorable outcomes. Thus, we sought 
to describe crude mortality rates of subsequent CDI episodes 
and identify independent predictors of mortality among our 
national cohort of Veterans with recurrence of Clostridium dif-
ficile infection.
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METHODS
Data Sources
We used data from national Veterans Affairs (VA) databases for 
this work. Corporate Data Warehouse (CDW), Medical SAS, 
and Decision Support System (DSS) data were accessed through 
the VA Informatics and Computing Infrastructure (VINCI). 
Our cohort included patients from 128 VA facilities nationally.
Study Population
We developed a national cohort of adult Veterans (≥18 years) 
with an initial CDI episode (no CDI episodes in the year prior) 
treated during an inpatient admission or outpatient encounter 
at a VA facility from May 1, 2010, to December 30, 2014. We 
defined a CDI episode as a positive stool sample for C. difficile 
toxin(s) and receipt of at least 2 days of standard CDI treatment 
(oral [PO] or intravenous [IV] metronidazole, PO or rectal [PR] 
vancomycin, or fidaxomicin) [1, 19]. Use of a minimum treat-
ment window of at least 2–3 days of CDI therapy (regardless of 
dosing frequency) has been used previously in several studies 
for CDI identification and minimum CDI treatment exposure 
[17, 20, 21]. Although a CDI testing method was not available in 
the data source, the use of the nucleic acid amplification test for 
CDI diagnostic testing among VA facilities has increased from 
33% in 2010 to 54% in 2012 to 81% in 2015 [22]. The initial 
episode was the first episode of CDI during the study period. 
First recurrence, second recurrence, and third recurrence were 
defined as subsequent CDI episodes at least 14 days after the 
positive stool test date and within 30 days of the end of treat-
ment of the prior occurrence [23–25]. An interval of at least 
14  days is commonly used to distinguish new recurrent epi-
sodes from prior CDI episodes [2, 26].
Study Design
We described the all-cause mortality rate by episode number. 
Mortality was defined as death from any cause within 30 days 
of the end date of CDI treatment of the prior CDI episode. We 
also conducted a case–control analysis in our cohort of patients 
with a first recurrence of CDI to identify independent predic-
tors of all-cause mortality. Cases were defined as patients who 
died from any cause within 30 days of the end of treatment of 
recurrence. Controls were survivors at 30  days from the end 
of treatment of recurrence and were matched to cases on year, 
facility, and severity. Four controls were matched to each case. 
Clostridium difficile infection severity was defined as severe 
if the closest white blood cell count was >15 ×  103/μL or the 
serum creatinine was >1.5 g/dL within 7 days of CDI treatment, 
nonsevere if the white blood cell count was ≤15 × 103/μL and 
the serum creatinine was ≤1.5  g/dL, or unknown otherwise 
[27]. In our overall cohort of patients with CDI, >96% of white 
blood cell count (n = 42 298) and serum creatinine (n = 40 261) 
levels were obtained within 2 days of treatment.
Potential predictors assessed were based on clinical rele-
vance and/or previously described predictors of poor outcomes 
[1, 28–31]. Potential predictors included demographics, 
treatment characteristics, current comorbidities and medi-
cal history, aggregate comorbidity burden using the Charlson 
Comorbidity Index, laboratory results, current and previous 
health care exposures, and concurrent and previous medication 
exposures. We defined CDI treatment as metronidazole PO or 
IV monotherapy, vancomycin PO or PR monotherapy, vanco-
mycin and metronidazole combination therapy, or fidaxomicin 
alone or in combination with vancomycin and/or metronida-
zole. We compared metronidazole monotherapy with all other 
treatment options due to the high frequency of metronidazole 
monotherapy in our cohort. International Classification of 
Diseases, 9th Revision (ICD-9), diagnosis and procedure codes 
were used to identify the presence of current and previous dis-
ease states and procedures. Current comorbidities were defined 
as disease states that occurred during the index CDI admission 
(inpatient) or 30 days before the CDI episode (outpatient) and 
medical histories were defined as those that occurred in the year 
before the CDI episode. Clinical Classifications Software (CCS) 
for ICD-9 codes was used to categorize diagnoses and proce-
dures into broader disease states [32]. Medication exposures 
assessed included antibiotics, gastric acid suppressants, immu-
nosuppressants, laxatives, and supplemental medications (pro-
biotics, binding agents, rifampin, rifaximin, nitazoxanide, and 
bacitracin). Medication exposures were assessed before CDI 
treatment (30 days prior for immunosuppressants and antibiot-
ics and 7 days for gastric acid suppressants, histamine receptor 2 
antagonists [H2RA], or proton pump inhibitors [PPIs]), during 
CDI treatment, and 30 days after CDI treatment. The window 
for assessment of exposure to medications was selected based 
on clinical relevance or previous work [3, 9, 31].
Statistical Analysis
We calculated descriptive statistics, including number, per-
centage, mean (standard deviation), and median (interquartile 
range). Differences in clinical characteristics and crude mortal-
ity rates by episode number were analyzed using the chi-square 
test or Fisher exact test for categorical data and the Student t test 
or Wilcoxon rank-sum test for continuous data, as appropriate. 
We also analyzed differences between cases and controls and 
used backward, manual, stepwise conditional logistic regression 
to identify independent predictors of mortality [33]. All varia-
bles with a P value of less than .10 from univariate analysis were 
included in subsequent multivariable analysis [33]. Variables 
were then removed in a stepwise fashion from the multivaria-
ble models until all remaining variables were significantly asso-
ciated with the outcome (P  <  .05) [33]. Multicollinearity was 
assessed using the correlation matrix of the final model and var-
iance inflation factor values [33, 34]. All variables in our final 
multivariable model had a variance inflation factor value of <3, 
indicating lack of multicollinearity. All statistical analyses were 
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The Institutional Review Board and the Research and 
Development Committee of the Providence Veterans Affairs 
Medical Center approved this study protocol before the study 
was initiated.
RESULTS
We identified 49 064 initial episodes of CDI, 2521 episodes of 
first recurrence, 409 episodes of second recurrence, and 68 
episodes of third recurrence over our 5-year study period. The 
mean age of patients with an initial CDI episode (SD) was 66.2 
(14.1) years. Mean age (SD) increased with each subsequent 
occurrence: 68.5 (13.1) years for first recurrence, 70.7 (13.4) 
years for second recurrence, and 73.2 (13.9) years for third 
recurrence. The majority of initial episodes (69.7%, n = 34 177) 
were treated in the outpatient setting. Significantly more epi-
sodes were treated in the outpatient setting for the initial episode 
as compared with the first recurrence (58%, n = 1462); however, 
with each subsequent recurrence, the percentage of patients 
treated in the outpatient setting remained stable (56.5% second 
recurrence, 55.9% third recurrence). Thirty-four percent of ini-
tial CDI episodes were severe (n = 16 806). The severity of most 
cases of recurrence was unknown (95.1% first, 97.6% second, 
100% third recurrence). The crude 30-day all-cause mortality 
rate was 10.6% for the initial episode (n = 5214), 8.3% for first 
recurrence (n = 208), 4.2% for second recurrence (n = 17), and 
5.9% for third recurrence. Crude 30-day all-cause mortality was 
significantly higher for the initial episode vs first recurrence 
(P < .001) and first recurrence vs second recurrence (P = .004).
We identified 110 cases who died within 30 days of end of 
treatment of the first recurrence and 440 surviving controls 
matched on year, facility, and severity. Characteristics of cases 
and controls are described in Table 1. The mean age (SD) of cases 
was 73.1 (12.5) years, and that of controls was 66.9 (13.1) years. 
Treatment in the outpatient setting (49.1% cases vs 65.0% con-
trols) and metronidazole monotherapy treatment (40.9% cases 
vs 71.4% controls) were less common in cases as compared with 
controls. Table 2 lists the 6 independent predictors of 30-day all-
cause mortality identified. Medication exposures predictive of 
mortality included use of proton pump inhibitors within 7 days 
before CDI treatment (odds ratio [OR], 3.86; 95% confidence 
interval [CI], 2.14–6.96) and any non-CDI antibiotic use during 
CDI treatment (OR, 3.33; 95% CI, 1.79–6.17). For comorbidi-
ties and medical history, current respiratory failure (OR, 8.26; 
95% CI, 1.71–39.92), current congitive dysfunction (OR, 2.41; 
95% CI, 1.02–5.72), and medical history of nutrition deficiency 
(OR, 2.91; 95% CI, 1.37–6.21) were predictive of mortality. Age 
was also a predictor of mortality (OR, 1.04; 95% CI, 1.01–1.07).
DISCUSSION
This study is the first to identify independent predictors of 
mortality among a national cohort of Veterans who already 
experienced an initial and subsequent first recurrence of CDI. 
Although several prior studies have studied the risk factors for 
mortality in patients with CDI, to our knowledge, ours is the 
first to focus specifically on evaluating predictors of mortality 
in patients with a first recurrence of CDI. From the time of 
the first recurrence of CDI (second CDI episode per patient), 
we followed patients to determine whether they died and then 
identified predictors of death.
In addition to identifying predictors, our study described 
crude mortality rates by subsequent episode. Our results are 
supported by another recent VA analysis among 30 326 VHA 
beneficiaries nationally, which also found higher 30-day mor-
tality rates among those with initial disease (21%) than those 
with recurrent disease (11% with first recurrence and 7% with 
second recurrence) [35]. Another study among 1527 adults 
diagnosed with CDI in a hospital in Canada described decreas-
ing mortality rates with subsequent CDI episodes (10.9% ini-
tial, 7.6% first recurrence, 7.0% second recurrence, 5.7% third 
recurrence) [16]. Possible explanations for decreased mortality 
with recurrent disease include a survival bias among patients 
who survive an initial episode, earlier disease detection and 
treatment among those who recur as compared with those with 
initial disease, and host-adaptive immune response changes 
[35]. Another possible explanation for findings may be related 
to the difficulties in distinguishing symptomatic recurrent CDI 
from those with alternative etiologies for continued diarrhea. 
A  retrospective review of 117 patients referred for treatment 
for presumed recurrent CDI found that 25% did not actually 
have CDI but had an alterative diagnosis, usually postinfectious 
inflammatory bowel syndrome [36].
Similar to our findings, previous studies have demonstrated 
that older age and comorbid conditions are independent risk 
factors for mortality in patients with CDI [9, 11, 12]. A system-
atic review that included 30 studies demonstrated that increas-
ing age and underlying comorbid conditions, including both 
individual conditions (specifically malignancy, chronic renal 
failure, and coronary artery disease) and aggregate Charlson 
score, were among the most commonly reported risk factors for 
mortality in patients with CDI [9]. One of the major reasons 
for an increased risk of poor outcomes, including mortality, in 
older patients and/or those with serious comorbid conditions 
may be a decreased ability to mount an adequate immune 
response to the C. difficile toxin [37]. Age has been recognized 
as a risk factor for both development of CDI and CDI-related 
death [28]. A recent study that used the US 2011 Nationwide 
Inpatient Sample (NIS) database and included more than 77 000 
CDI hospitalizations found that progressive increase in age was 
an independent predictor of CDI-associated in-hospital mor-
tality, especially in patients age 81–100  years (OR, 4.12; 95% 
CI, 3.39–4.99) as compared with those age 18–40  years [38]. 
Previous work evaluating predictors of complicated CDI (death, 
need for colectomy, shock, perforation, or megacolon within 
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Table 1. Patient Characteristics, 30-Day All-Cause Mortality
Cases With 30-d All-Cause 
Mortality (n = 110)
Controls Without 30-d  
All-Cause Mortality (n = 440)
Age, mean (SD), yc 73.1 (12.5) 66.9 (13.1)
Male gender, n (%) 109 (99.1) 419 (95.2)
White race, n (%) 80 (72.7) 326 (74.1)
Hispanic ethnicity, n (%) 7 (6.4) 23 (5.2)
Married, n (%) 48 (43.6) 180 (40.9)
Treatment setting, n (%)c
 Acute care 46 (41.8) 140 (31.8)
 Long-term care 10 (9.1) 14 (3.2)
 Outpatient 54 (49.1) 286 (65.0)
CDI treatment, n(%)c
 Metronidazole PO/IV monotherapy 45 (40.9) 314 (71.4)
 Metronidazole monotherapy 45 (40.9) 314 (71.4)
 PO monotherapy 28 (25.5) 251 (57.0)
 IV monotherapy 17 (15.5) 63 (14.3)
 Vancomycin PO monotherapy 26 (23.6) 74 (16.8)
 Metronidazole PO/IV & vancomycin PO 39 (35.5) 50 (11.4)
CDI treatment duration, median (IQR), d 7 (11–4) 8 (4–15)
Charlson comorbidity score, median (IQR)c 3 (0–5) 1 (0–4)
Current comorbidities, n (%)a
 Abdominal pain <5 27 (6.1)
 Alcoholic disorder 8 (7.3) 26 (5.9)
 Atherosclerosis 15 (13.6) 61 (13.9)
 Bacterial infection (unspecified site) 8 (7.3) 34 (7.7)
 Cerebrovascular disease <5 8 (1.8)
 Chronic renal disease 21 (19.1) 63 (14.3)
 Chronic obstructive pulmonary disease 16 (14.5) 58 (13.2)
 Diabetes mellitus 12 (10.9) 70 (15.9)
 Esophageal disorder 6 (5.5) 25 (5.9)
 Fever of unknown origin <5 14 (3.2)
 Heart failurec 21 (19.1) 49 (11.1)
 Hypertension 24 (21.8) 96 (21.8)
 Liver disease 9 (8.2) 22 (5.0)
 Myocardial infarction <5 6 (1.4)
 Nutrition deficiencyc 20 (18.2) 23 (5.2)
 Osteoarthritis <5 10 (2.3)
 Peptic ulcer disease <5 <5
 Peripheral vascular disease 5 (4.5) 18 (4.1)
 Pulmonary heart diseasec 8 (7.3) 9 (2.0)
 Respiratory failurec 18 (16.4) 16 (3.6)
 Solid organ cancer 16 (14.5) 49 (11.1)
 Surgery/medical complication 6 (5.5) 12 (2.7)
Medical history, n (%)b
 Abdominal pain 8 (7.3) 50 (11.4)
 Alcoholic disorder 10 (9.1) 43 (9.8)
 Atherosclerosisc 38 (34.5) 104 (23.6)
 Bacterial infection (unspecified site) 20 (18.2) 76 (17.3)
 Cognitve dysfunctionc 21 (19.1) 30 (6.8)
 Cerebrovascular disease 6 (5.5) 17 (3.9)
 Chronic renal disease 27 (24.5) 87 (19.8)
 Chronic obstructive pulmonary disease 30 (27.3) 95 (21.6)
 Diabetes mellitus 28 (25.5) 126 (28.6)
 Esophageal disorder 24 (21.8) 82 (18.6)
 Fever of unknown origin 6 (5.5) 29 (6.6)
 Heart failurec 30 (27.3) 78 (17.7)
 Hypertension 55 (50.0) 181 (41.1)
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during 1991–2005 with first recurrence identified older age as a 
strong predictor [14].
Several comorbid conditions have been previously identified 
as predictors of mortality in patients with CDI [13, 38]. Our 
work demonstrated that respiratory failure, cognitive dysfunc-
tion, and nutrition deficiency were all independent predictors of 
mortality. Respiratory failure has been previously identified as 
an independent predictor of mortality in patients with fulminant 
C. difficile colitis [39]. Intensive care unit admission and acute 
renal failure were among the among the strongest predictors of 
CDI-associated in-hospital mortality identified in the study of 
CDI hospitalizations using 2011 NIS data, and although we did 
not identify these conditions as independent predictors, res-
piratory failure may represent a related surrogate marker [38]. 
Functional decline has previously been associated with severe 
CDI, and dependency in activities of daily living has been asso-
ciated with long-term mortality in very old patients with CDI 
[40, 41]. The diagnosis codes for cognitive dysfunction include 
delirium, dementia, and amnestic and other cognitive disor-
ders [32]. To our knowledge, nutrition deficiency has not been 
previously identified as an independent predictor; however, 
conditions that may cause or be related to various nutrition 
deficiencies have been identified as independent predictors 
of mortality, such as enteral tube feeding and inflammatory 
bowel disease [38, 42, 43]. Although enteral tube feeding and 
inflammatory bowel disease are not included in the codes 
for nutrition deficiency, nutrition deficiency codes capture a 
broad spectrum of nutritional conditions, such as unspecified 
protein-calorie malnutrition, other malnutrition, cachexia, 
and vitamin deficiencies [32]. It is possible that some enteral 
tube feeding diets may lead to nutrition deficiencies in the 
colon and resultant disruption on the colonic microbiota [42]. 
Additionally, the mortality risk has consistently been shown to 
be higher in CDI patients with inflammatory bowel disease, a 
Cases With 30-d All-Cause 
Mortality (n = 110)
Controls Without 30-d  
All-Cause Mortality (n = 440)
 Myocardial infarction 5 (4.5) 14 (3.2)
 Nutrition deficiencyc 30 (27.3) 39 (8.9)
 Osteoarthritis 13 (11.8) 40 (9.1)
 Peptic ulcer disease 5 (4.5) 12 (2.7)
 Peripheral vascular disease 11 (10.0) 49 (11.1)
 Pulmonary heart disease 7 (6.4) 21 (4.8)
 Solid organ cancer 26 (23.6) 72 (16.4)
 Surgery/medical complication 14 (2.7) 36 (8.2)
Medication exposures, n (%)
 Non-CDI antibiotic use, 30 d before Clostridium difficile 
infection treatmentc
93 (84.5) 314 (71.4)
 Non-CDI antibiotic use, during Clostridium difficile infection 
treatmentc
82 (74.5) 213 (48.4)
 Non-CDI antibiotic use, 30 d after Clostridium difficile infec-
tion treatment
36 (32.7) 154 (35.0)
 Histamine receptor 2 antagonist use, 7 d before Clostridium 
difficile infection treatment
11 (10.0) 28 (6.4)
 Proton pump inhibitor use, 7 d before Clostridium difficile 
infection treatmentc
68 (61.8) 156 (35.5)
 Histamine receptor 2 antagonist use, 30 d after Clostridium 
difficile infection treatment
7 (6.4) 49 (11.1)
 Proton pump inhibitor use, 30 d after Clostridium difficile 
infection treatment
42 (38.2) 165 (37.5)
 Probiotic use, 30 d after Clostridium difficile infection 
treatment
5 (4.6) 36 (8.2)
 Immunosuppressant use, 30 d after Clostridium difficile 
infection treatment
13 (11.8) 55 (12.5)
Hospitalization, prior 90 d, n (%) 88 (80.0) 342 (77.7)
Long-term care admission, prior 90 d, n (%)c 11 (10.0) 20 (4.6)
Recurrent CDI in hospital setting, n (%) 57 (51.8) 155 (35.2)
Length of stay, median (IQR), dc 13 (8–21) 7 (4–13)
Current comorbidities and medical histories were defined using Clinical Classification Software
for ICD-9.
Abbreviations: CDI, Clostridium difficile infection; IQR, interquartile range; IV, intravenous; PO, oral.
aCurrent comorbidities were defined as diagnoses that occurred during the index CDI admission (inpatient) or 30 days before the CDI episode (outpatient).
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population at risk for a number of nutrition deficiencies [38, 
43].
Although several individual conditions were associated with 
CDI, aggregate comorbidity burden was not identified as an 
independent predictor. Most previous work has identified the 
Charlson Comorbidity Index as an independent predictor of 
mortality; however, similar to our findings, other studies have 
not identified the Charlson Comorbidity Index as an inde-
pendent predictor of mortality or poor outcomes [9, 42, 44]. 
The performance of aggregate comorbidity scores in predict-
ing mortality is largely dependent on the underlying charac-
teristics of the population under study [45, 46]. Additionally, 
scores developed specifically to predict risk of death associated 
with CDI have been found to outperform Charlson comorbid-
ity scores. As such, future work developing such a score in the 
Veteran population is warranted [38].
Another potential factor associated with mortality sup-
ported by our findings is continued disruption in the normal 
colonic microbiota [37]. We found that concurrent use of any 
non-CDI antibiotic and use of proton pump inhibitors within 
7 days before CDI treatment were independent risk factors for 
mortality. Antibiotic use is a well-established risk factor for the 
development of incident and recurrent CDI, and there is also 
evidence of an association between continued non-CDI anti-
biotic use and poor outcomes in patients with CDI [10, 47–50]. 
Continued use of antibiotics following CDI diagnosis (OR, 2.01; 
95% CI, 1.01–3.99) was the strongest predictor of complicated 
CDI (death or need for colectomy within 30  days after CDI 
onset) identified in a hospital-based study [10]. In a single study 
among 421 patients at an academic, urban, tertiary care hos-
pital in the United States, longer courses of antibiotics during 
the index CDI hospitalization were significantly associated with 
mortality within 180 days [13]. It is important to note that ongo-
ing non-CDI active antibiotic therapy may be necessary and 
unavoidable in patients with concomitant infections in addition 
to their CDI, and both infections together may increase their 
risk of death. There are several studies that link PPI use with 
CDI recurrence, and there is even limited evidence that gas-
tric acid suppression is associated with increased odds of death 
in patients with CDI [9, 51]. However, PPIs are commonly 
given to patients who are severely ill, have a number of serious 
comorbid conditions, and are frequently exposed to antibiotics 
[10, 52]. The effect of PPIs on death may differ depending on 
these factors.
There are limitations to this work. Our definition of CDI does 
not distinguish between symptomatic episodes and asympto-
matic carriage. We attempted to include only patients treated 
for CDI by requiring at least 2  days of standard CDI treat-
ment [17, 20, 21]. In an attempt to include the most severely 
ill patients who could not tolerate any medications by mouth, 
we included patients treated with intravenous metronidazole 
only [1]. Additionally, accurate identification of recurrent dis-
ease from administrative data is very challenging [53]. Previous 
work has shown that the performance of diagnosis codes, labo-
ratory data, or medication data used alone to accurately identify 
recurrent disease was poor, and performance only improved 
moderately when used in combination [53]. We were unable to 
perform chart reviews to confirm the diagnosis of CDI recur-
rence in our cohort. Our work is thus limited in that we are not 
able to determine if the reduction in crude mortality rates that 
we observed among those with recurrences was due to contin-
ued symptoms of diarrhea due to alterative etiologies, such as 
postinfectious inflammatory bowel syndrome, vs true recurrent 
infection. Another limitation is that we are unable to account 
Table 2. Independent Predictors of 30-Day All-Cause Mortality
Predictor Adjusted Odds Ratio Lower 95% Confidence Limit Upper 95% Confidence Limit
Medications used before Clostridium difficile infection treatment
 Proton pump inhibitor (within 7 d before) 3.86 2.14 6.96
Concurrent medications used during Clostridium difficile infection treatment
 Any antibiotica 3.33 1.79 6.17
Current comorbidities
 Respiratory failure 8.26 1.71 39.92
Medical history
 Nutrition deficiency 2.91 1.37 6.21
 Cognitve dysfunction 2.41 1.02 5.72
Demographics
 Ageb 1.04 1.01 1.06
Adjusted odds ratios are estimated from multivariate analysis of the data. The final multivariate logistic regression model included 11 variables, including all predictive variables listed in 
the table above (odds ratio >1) and also the following variables with odds ratios <1: clindamycin use within 30 days before Clostridium difficile infection treatment, histamine receptor 2 
antagonist use within 30 days after Clostridium difficile infection treatment, medical history of respiratory failure, metronidazole monotherapy for Clostridium difficile infection vs all other 
treatments, and treatment duration.
aAny antibiotic included any antibiotic not used for the treatment of Clostridium difficile infection, including the following antibiotic classes/agents: aminoglycosides, aztreonam, β-lactam/ 
β-lactamase inhibitor combinations, carbapenems, cephalosporins, clindamycin, fluoroquinolones, fosfomycin, glyco-/glycolipo-/lipopeptdes (except vancomycin oral/rectal), nitrofurantoin, 
macrolides, oxazolidinones, penicillins, polymyxins, sulfamethoxazole/trimethoprim, quinupristin-dalfopristin, tetracyclines, and tigecycline.
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for possible treatment or care received outside the VA system; 
therefore, we may have underestimated certain exposures, in 
particular over-the-counter proton pump inhibitors, histamine 
receptor 2 antagonists, and probiotics, or misclassified recur-
rence if patients were treated in non-VA settings. Our definition 
of severity is limited in that it was based in part on a single-se-
rum creatinine level near CDI treatment initiation and labora-
tory values to determine severity were missing in a majority of 
our study population. We selected severity a priori as a match-
ing factor in our statistical analysis plan as it is a known pre-
dictor of poor outcomes. We only assessed poor outcomes up 
to 30 days after CDI treatment, and there is thus the potential 
for underestimation of recurrence and death that occurred after 
that follow-up period. Most patients have recurrence within 
30 days; however, 20% of patients may have another episode of 
CDI within 180 days of CDI treatment cessation [54]. We con-
sidered several risk factors for mortality in patients with CDI 
that have been previously described; however, there may be 
other known and unknown risk factors that were not included 
in our study. Additionally, the accuracy of using ICD-9 codes 
for identifying comorbidities and previous medical histories 
varies by disease state. Thus, our predictive analysis is limited 
by the variables included in the model. Generalizability to the 
general population may be limited.
CONCLUSIONS
In our national cohort of Veterans with CDI, crude mortality 
decreased by 44% from the initial episode to the third recur-
rence. Treatment with antibiotics, use of PPIs, and underlying 
comorbidities were important predictors of mortality within 
30 days of the end of treatment of CDI recurrence. Our data are 
among the first to investigate predictors of mortality in patients 
with an initial episode and subsequent recurrence and will 
assist health care providers in identifying patients at high risk of 
mortality after a first recurrence of CDI.
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